PYPD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

PYPD ▼ -1.36% at T+20d

LONG call ✗ call lost -1.36% · α vs SPY -9.09% · entry $4.40 → $4.34

Next anchor: T+60d in 28d

Currently $4.57 · +3.86% from $4.40 entry

Entry anchored
Apr 10, 03:59 PM ET
via Databento tick

T+1d

+0.45%

call +0.45% · α -0.76%

$4.42

settled 8w ago

T+5d

+6.59%

call +6.59% · α +3.30%

$4.69

settled 7w ago

T+20d

-1.36%

call -1.36% · α -9.09%

$4.34

settled 4w ago

T+60d

—

call — · α —

—

in 28d

Price Chart

Loading chart...

Executive Summary

PolyPid announced new pharmacokinetic data from its Phase 3 SHIELD II trial showing sustained, controlled release of D-PLEX₁₀₀ with detectable doxycycline levels at the surgical site for up to 32 days and minimal systemic exposure. The data will be presented at ESCMID Global 2026, reinforcing the drug’s mechanism of action for preventing surgical site infections.

Actionable Insight

Traders should view this as a validation of D-PLEX₁₀₀’s pharmacokinetic profile, strengthening its differentiation and regulatory pathway. With FDA Breakthrough status and strong Phase 3 data already demonstrated, this reinforces near-term approval potential and partnership prospects, especially in a high-unmet-need area like surgical infections.

Key Facts

D-PLEX₁₀₀ showed detectable doxycycline concentrations for up to 763 hours (32 days) post-surgery with no burst release.
Plasma concentrations remained below 100 ng/mL, indicating negligible systemic exposure compared to oral doxycycline (Cmax ~1,600–2,600 ng/mL).
Data supports D-PLEX₁₀₀’s mechanism: localized, prolonged antibiotic delivery over 30 days at surgical site.
D-PLEX₁₀₀ previously demonstrated 60% relative risk reduction in SSIs (p=0.0013) in the SHIELD II trial.
D-PLEX₁₀₀ has FDA Breakthrough Therapy designation for SSI prevention in elective colorectal surgery.

Financial Impact

Positive catalyst for regulatory momentum and commercial potential; no direct financials reported.

revenuevaluationdilution

Risk Factors

Forward-looking statements are subject to regulatory delays or rejection.
Commercial adoption may depend on physician behavior and reimbursement dynamics.
Company has limited market cap ($82M), making it highly sensitive to sentiment and liquidity risks.

Market Snapshot

Exchange

Nasdaq

Sector

Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3272567

9 reports for PYPD

T+1T+5T+20T+60

67% Hit rate 4 of 6 directional calls best @ T+5▲ +12.80%May 13, 2026

Filters

Reports for PYPD — sortable, filterable
	Type				Now
Jun 1, 2026 8d ago	6-K BULLISH ★ 7/10	$5.07 $4.50	▼ −11.24%	▼ −8.49%	$4.57 (−9.86%)
Jun 1, 2026 8d ago	Press Release BULLISH ★ 7/10	$5.07 $4.50	▼ −11.24%	▼ −8.49%	$4.57 (−9.86%)
May 20, 2026 20d ago	Press Release NEUTRAL ★ 3/10	$4.85 $4.77	▼ −1.65%	▼ −2.89%	$4.57 (−5.77%)
May 13, 2026 27d ago	6-K BULLISH ★ 7/10	$4.22 $4.76	▲ +12.80%	▲ +13.95%	$4.57 (+8.29%)
May 13, 2026 27d ago	Press Release BULLISH ★ 7/10	$4.22 $4.76	▲ +12.80%	▲ +13.95%	$4.57 (+8.29%)
Apr 13, 2026 8w ago	Press Release BULLISH ★ 7/10	$4.40 $4.69	▲ +6.59%	▲ +3.30%	$4.57 (+3.86%)
Apr 6, 2026 9w ago	3 NEUTRAL ★ 3/10	$4.24 $4.40	▲ +3.77%	▼ −0.36%	$4.57 (+7.78%)
Mar 31, 2026 10w ago	6-K BULLISH ★ 8/10	$4.38 $4.23	▼ −3.42%	▼ −7.37%	$4.57 (+4.34%)
Mar 31, 2026 10w ago	Press Release BULLISH ★ 7/10	$4.38 $4.23	▼ −3.42%	▼ −7.37%	$4.57 (+4.34%)

US Market Status

Market Closed — Opens Thu (11h 9m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access